Illidge TM: Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? J Clin Oncol 2010, 28: 2944–2946. 10.1200/JCO.2009.26.8748
Article
PubMed
Google Scholar
Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Bischof Delaloye AB, Press OW, Ketterer N: Six of 12 relapsed refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med 2011, 52: 896–900. 10.2967/jnumed.111.087460
Article
PubMed
Google Scholar
Kaminski MS, Zelenetz AD, Press OW, Saleh MN, Leonard JP, Fehrenbacher L, Lister TA, Horner TJ, Williams VC, Lin TS, Vleisides C, Knox SJ, Wahl RL, Vose MJ: Tositumomab and I 131 Tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low grade and transformed B-cell lymphomas. Blood 2010, 116: Abstract 3960.
Google Scholar
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006, 24: 4143–4149. 10.1200/JCO.2006.05.8198
Article
CAS
PubMed
Google Scholar
Martin P, Coleman M, Furman RR, Vallabhajosula S, Kim DS, Edelstein A, Morrison J, Elstrom R, Ruan J, Goldsmith SJ, Leonard JP: Fludarabine plus I-131 tositumomab as initial treatment for follicular lymphoma: half of patients in remission at over 10 years median followup. Blood 2010, 116: Abstract 1785.
Google Scholar
Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352: 441–449. 10.1056/NEJMoa041511
Article
CAS
PubMed
Google Scholar
Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007, 109: 1804–1810. 10.1002/cncr.22617
Article
CAS
PubMed
Google Scholar
Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez GM, Petrini M, Sebban C, Zinzani PL, van Oers MHJ, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26: 5156–5164. 10.1200/JCO.2008.17.2015
Article
CAS
PubMed
Google Scholar
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377: 42–51. 10.1016/S0140-6736(10)62175-7
Article
CAS
PubMed
Google Scholar
Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996, 14: 1282–1290.
CAS
PubMed
Google Scholar
Sharkey RM, Weadock KS, Natale A, Haywood L, Aninipot R, Blumenthal RD, Goldenberg DM: Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 1991, 83: 627–632. 10.1093/jnci/83.9.627
Article
CAS
PubMed
Google Scholar
Vogel CA, Galmiche MC, Buchegger F: Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res 1997, 57: 447–453.
CAS
PubMed
Google Scholar
Sharkey RM, Karacay H, Goldenberg DM: Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. Cancer 2010, 116: 1134–1145. 10.1002/cncr.24802
Article
CAS
PubMed Central
PubMed
Google Scholar
Buchegger F, Press OW, Delaloye Bischof A, Ketterer N: Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Oncologist 2008, 13: 657–667. 10.1634/theoncologist.2008-0020
Article
PubMed
Google Scholar
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H, for the Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators: Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011, 12: 460–468. 10.1016/S1470-2045(11)70069-9
Article
CAS
PubMed
Google Scholar
Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM: Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008, 112: 830–835. 10.1182/blood-2008-01-132142
Article
CAS
PubMed Central
PubMed
Google Scholar